SIGA Technologies, Inc. (SIGA)

8.76 +0.41 (+4.91%) At close: 04:00PM EDT

SIGA Technologies, Inc.

31 East 62nd Street
New York, NY 10065
United States
212 672 9100
https://www.siga.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 45

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Daniel J. Luckshire	Executive VP, CFO & Secretary	1.38M	N/A	1971
Dr. Dennis E. Hruby	Executive VP & Chief Scientific Officer	1.41M	N/A	1952
Dr. Jay K. Varma M.D.	Executive VP, Chief Medical Officer & Director	6.24k	N/A	1972
Ms. Tove C. Bolken	Senior VP of Operations & Chief Supply Chain Officer	N/A	N/A	N/A
Mr. Herb Vloedman	Senior VP & Chief Information Officer	N/A	N/A	N/A
Mr. Lawrence R. Miller Esq., J.D.	General Counsel	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Corporate governance

SIGA Technologies, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 2; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.